Is IOVA or KLRS more undervalued in 2026?

CirclFi compares Iovance Biotherapeutics, Inc. (IOVA) and Kalaris Therapeutics, Inc. (KLRS) using 13 institutional-grade valuation models. IOVA has a Quality of Company score of 5.1/10 while KLRS scores 4.1/10.

Which is a better buy — IOVA or KLRS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do IOVA and KLRS valuations compare?

IOVA at $4.10 and KLRS at $5.27 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

IOVA vs KLRS Valuation Comparison 2026 — Intrinsic Value Analysis

IOVA

Biological Products, (No Diagnostic Substances)

Iovance Biotherapeutics, Inc.

Quality

5.1

out of 10

Value Trap

SAFE

Price

$4.10

Last close

Models

11/13

Active

KLRS

Biological Products, (No Diagnostic Substances)

Kalaris Therapeutics, Inc.

Quality

4.1

out of 10

Value Trap

LOW

Price

$5.27

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	IOVA Fair Value	IOVA Upside	KLRS Fair Value	KLRS Upside
Bayesian DCF	Intrinsic	$1.12	-72.7%	$0.38	-92.7%
Earnings Power Value	Intrinsic	$0.72	-78.7%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$1.69	-58.8%	$1.17	-77.7%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for IOVA vs KLRS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

IOVA vs KLRS — Which Stock Is More Undervalued?

IOVA scores higher with a 5.1/10 quality rating vs KLRS's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Iovance Biotherapeutics, Inc. (IOVA) and Kalaris Therapeutics, Inc. (KLRS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

IOVA currently trades at $4.10 with a QOC of 5.1/10, while KLRS trades at $5.27 with a QOC of 4.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).